EconStor >
Stockholm School of Economics >
EFI - The Economic Research Institute, Stockholm School of Economics >
SSE/EFI Working Paper Series in Economics and Finance, EFI - The Economic Research Institute, Stockholm School of Economics >

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10419/56332
  

Full metadata record

DC FieldValueLanguage
dc.contributor.authorJönsson, Linusen_US
dc.contributor.authorBorgström, Fredriken_US
dc.contributor.authorZethraeus, Niklasen_US
dc.date.accessioned2012-03-28T13:10:31Z-
dc.date.available2012-03-28T13:10:31Z-
dc.date.issued2002en_US
dc.identifier.urihttp://hdl.handle.net/10419/56332-
dc.description.abstractBackground: The Fracture Intervention Trial (FIT) showed that the bisphosphonate alendronate reduces the risk of fractures in women with low bone mass in the United States. Objective: To estimate the cost-effectiveness (cost per life-year gained and cost per quality-adjusted life-year, QALY, gained) of treating osteoporotic women in Denmark with alendronate, compared with no treatment. Design: A Markov model earlier used in the economic evaluation for Sweden was adapted using epidemiological and cost data for Denmark. In the base-case alendronate was assumed to have a fracture-risk reducing effect for ten years; a treatment duration period of 5 years followed by a 5-year period where the effect declined linearly to zero. Results: Treating a 71-year old (the mean age in the vertebral arm of the FIT) osteoporotic woman with one prior vertebral fracture with alendronate was found to be associated with a cost of DKK 52,311 per QALY gained. The cost-effectiveness ratio when treating a 69-year old woman with low bone mass and without previous vertebral fractures was higher (DKK 205,816) but still within the limits of what can be considered good value for money. Conclusions: The results of this study indicate that treatment with alendronate in Denmark is cost-effective, provided the treatment is targeted towards high-risk patients corresponding to the patient groups in the FIT study.en_US
dc.language.isoengen_US
dc.publisherEkonomiska Forskningsinst. Stockholmen_US
dc.relation.ispartofseriesSSE/EFI Working Paper Series in Economics and Finance 501en_US
dc.subject.jelI10en_US
dc.subject.jelI19en_US
dc.subject.ddc330en_US
dc.subject.keywordosteoporosisen_US
dc.subject.keywordcost-effectivenessen_US
dc.subject.keywordquality of lifeen_US
dc.subject.keywordMarkov modelsen_US
dc.subject.keywordacceptability curveen_US
dc.titleCost-effectiveness of alendronate in the treatment of osteoporois in Denmark: An economic evaluation based on the fracture intervention trialen_US
dc.typeWorking Paperen_US
dc.identifier.ppn349572674en_US
dc.rightshttp://www.econstor.eu/dspace/Nutzungsbedingungenen_US
Appears in Collections:SSE/EFI Working Paper Series in Economics and Finance, EFI - The Economic Research Institute, Stockholm School of Economics

Files in This Item:
File Description SizeFormat
349572674.pdf307.7 kBAdobe PDF
No. of Downloads: Counter Stats
Show simple item record
Download bibliographical data as: BibTeX

Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.